Abstract
The review includes the analysis of modern data about prevalence, clinical picture, endoscopic, morphological, immunological diagnosis and treatment of autoimmune gastritis (AIG). The incidence of AIG is 2–12% of all cases of chronic gastritis. The leading factor in pathogenesis is the formation of autoantibodies to parietal cells and intrinsic Castle factor. AIG is a significant risk factor for vitamin C, B12, and D deficiency. The clinical picture of AIG is nonspecific and may include gastroenterologic, hematologic, and neuropsychiatric syndromes. Morphological diagnosis is the most reliable method for assessing atrophic gastritis, allowing the assessment of the three dynamic stages of AIG. Immunological diagnostics include antibodies to parietal cells and are highly specific. There is no etiotropic and pathogenetic therapy for AIG. Cyanocobalamin replacement therapy is approved in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
